“…The investigators observed a gradual decrease in circulating anti‐insulin antibodies detectable over the course of 3 months, indicating a reduced immunoreactivity of the recombinant protein. A more extensive study 2 assessed the immunogenicity of rh‐insulin in diabetic patients who had never received insulin treatment and in diabetic patients who had already been treated with monocomponent (single animal species) insulin. In both studies, responses to rh‐insulin were compared with matched control groups receiving other forms of insulin treatment.…”